The Diagnosis and Management of Hirsutism

ABSTRACT

Approximately 10% of women of childbearing age are hirsute, which is defined as the presence of coarse terminal hairs in androgen-dependent areas on the face and body. It not only is a source of psychological discomfort but also may be a sign of an underlying medical condition. This article reviews the pathophysiology, diagnosis, evaluation, and treatment of hirsutism.

KEYWORDS

Hirsutism - hyperandrogenism - antiandrogens - hair removal

REFERENCES

• 1 Deplewski D, Rosenfield R. Role of hormones in pilosebaceous unit development.  Endocr Rev . 2000;  21 362-392
• 2 Ferriman D, Gallwey J D. Clinical assessment of body hair growth in women.  J Clin Endocrinol Metab . 1961;  21 1440-1447
• 3 Knoochenhauer E S, Key T J, Kahsar-Miller M, Waggoner W, Boots L R, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study.  J Clin Endocrinol Metab . 1998;  83 3078-3082
• 4 Azziz R, Carmina E, Sawaya M. Idiopathic hirsutism.  Endocr Rev . 2000;  21 347-362
• 5 Paus R, Cotsarelis G. Mechanisms of disease: the biology of hair follicles.  N Engl J Med . 1999;  341 491-497
• 6 Habif T P. Clinical Dermatology.  3rd ed. St. Louis: Mosby-Year Book 1996: 739-740
• 7 Jaworsky C, Gilliam A C. Update on dermatopathology: immunology of the human hair follicle.  Dermatol Clin . 1999;  17 561-569
• 8 Gilliam A C, Kremer I B, Yosida Y. et al . The human hair follicle: a reservoir of CD40+ B7-deficient Langerhans cells that repopulate epidermis after UVB exposure.  J Invest Dermatol . 1998;  110 422-427
• 9 Staricco R G. Amelanotic melanocytes in the outer sheath of the human hair follicle and their role in the repigmentation of regenerated epidermis.  Ann N Y Acad Sci . 1963;  100 239-255
• 10 Paus R. Immunology of the hair follicle. In: Bos JD, ed. Skin Immune System 2nd ed. Boca Raton, FL: CRC Press 1997: 377-398
• 11 Christoph T, Muller-Rover S, Audring H. et al . The human hair follicle immune system: cellular composition and immune privilege.  Br J Dermatol . 2000;  142 862-873
• 12 Speroff L, Glass R H, Kase N G. Clinical Gynecologic Endocrinology and Infertility 6th ed. Philadelphia: Lippincott Williams & Wilkins; 1999 40-51: 523-556
• 13 Chuong C-M. Molecular Basis of Epithelial Appendage Morphogenesis: Molecular Biology Intelligence Unit 1.  Austin, TX: RG Landes; 1998
• 14 Zhou P, Byrne C, Jacobs J, Fuchs E. Lymphoid enhancing factor 1 directs hair follicle patterning and epithelial cell fate.  Genes Dev . 1995;  9 100-113
• 15 Hardy M H. The secret life of the hair follicle.  Trends Genet . 1992;  8 55-61
• 16 Ebling F J. Hair.  J Invest Dermatol . 1976;  67 98-105
• 17 Messenger A G. The control of hair growth: an overview.  J Invest Dermatol . 1993;  101 4S-9S
• 18 Lindner G, Botchkarev V A, Botchkareva N V. et al . Analysis of apoptosis during hair follicle regression.  Am J Pathol . 1997;  151 1601-1617
• 19 Lorenzo E M. Familial study of hirsutism.  J Clin Endocrinol . 1970;  31 556-564
• 20 Hatch R, Rosenfield R L, Kim M H, Tredway D. Hirsutism: implications, etiology, and management.  Am J Obstet Gynecol . 1981;  140 815-830
• 21 Hock D, Seifer D. New treatments of hyperandrogenism and hirsutism.  Obstet Gynecol Clin . 2000;  27 567-581
• 22 Berek J, Adash E, Hillard P. Novaks' Gynecology.  12th ed. Baltimore: Williams & Wilkins 1996: 834-836
• 23 Ryan K J. Biological aromatization of steroids.  J Biol Chem . 1959;  234 234-268
• 24 Ryan K J, Smith O W. Biogenesis of steroid hormones in the human ovary.  Recent Prog Horm Res . 1965;  21 367
• 25 Azziz R, Zacur H A. 21-Hydroxylase deficiency in female hyperandrogenism: screening and diagnosis.  J Clin Endocrinol Metab . 1989;  69 577-584
• 26 Glickman S P, Rosenfield R L. Androgen metabolism by isolated hairs from women with idiopathic hirsutism is usually normal.  J Invest Dermatol . 1984;  82 62-66
• 27 Wiebe R H, Morris C V. Effect of an oral contraceptive on adrenal and ovarian androgenic steroids.  Obstet Gynecol . 1984;  63 12-14
• 28 Barnes R B. Diagnosis and therapy of hyperandrogenism.  Baillieres Clin Obstet Gynaecol . 1997;  11 369-396
• 29 Lobo R A. Ovarian hyperandrogenism and androgen-producing tumors.  Endocrinol Metab Clin North Am . 1991;  20 773-805
• 30 Ehrman D A, Barnes R B, Rosenfield R L. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion.  Endocr Rev . 1995;  16 322-353
• 31 Barnes R B, Rosenfield R L, Burstein S, Ehrman D A. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome.  N Engl J Med . 1989;  320 559-565
• 32 Rosenfield R L, Barnes R B, Ehrman D A. Studies of the nature of 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism.  J Clin Endocrinol Metab . 1994;  79 1686-1692
• 33 Chetkowski R J, Defazio J, Shamonki I. et al . The incidence of late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency in hirsute women.  J Clin Endocrinol Metab . 1984;  58 595-598
• 34 Kutten F, Coullin P, Girard F. et al . Late-onset adrenal hyperplasia in hirsutism.  N Engl J Med . 1985;  313 224-231
• 35 White P C, New M I, Dupont B. Congenital adrenal hyperplasia.  N Engl J Med . 1987;  316 1580-1586
• 36 Carmina E. Prevalence of idiopathic hirsutism.  Eur J Endocrinol . 1998;  139 421-423
• 37 Mowszowicz I, Melanitou E, Doukani A. et al . Androgen binding capacity and 5α-reductase activity in pubic skin fibroblasts from hirsute patients.  J Clin Endocrinol Metab . 1983;  56 1209-1213
• 38 Couzinet B, Pholsena M, Young J, Schaison G. The impact of a pure anti-androgen (flutamide) on LH, FSH, androgens and clinical status in idiopathic hirsutism.  Clin Endocrinol (Oxf) . 1993;  39 157-162
• 39 Thorneycroft I H. Current issues in oral contraceptive therapy: update on androgenicity.  Am J Obstet Gynecol . 1999;  180 288-294
• 40 Azziz R, Ochoa T M, Bradley Jr L E. et al . Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study.  J Clin Endocrinol Metab . 1995;  80 3406-3411
• 41 Heiner J S, Greendale G A, Kawakami A K. et al . Comparison of a gonadotropin-releasing hormone agonist and a low does oral contraceptive given alone or together in the treatment of hirsutism.  J Clin Endocrinol Metab . 1995;  80 3412-3418
• 42 Chang R J, Laufer L R, Meldrum D R. et al . Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist.  J Clin Endocrinol Metab . 1983;  56 897-903
• 43 Andreyko J L, Monroe S E, Jaffe R B. The treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin).  J Clin Endocrinol Metab . 1986;  63 854-859
• 44 Steingold K, De Ziegler D, Cedars M. et al . Clinical and hormonal effect of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease.  J Clin Endocrinol Metab . 1987;  65 773-778
• 45 Rittmaster R S. Differential suppression of testosterone and estradiol in hirsute women with the superactive gonadotropin-releasing hormone agonist leuprolide.  J Clin Endocrinol Metab . 1988;  67 651-655
• 46 Falsetti L, Pasinetti E. Treatment of moderate and severe hirsutism by gonadotropin-releasing hormone agonists in women with polycystic ovarian syndrome and idiopathic hirsutism.  Fertil Steril . 1991;  56 427-433
• 47 Elkind-Hirsch K E, Anania C, Mack M, Malinak R. Combination gonadotropin-releasing hormone agonist and oral contraceptive therapy improves treatment of hirsute women with ovarian hyperandrogenism.  Fertil Steril . 1995;  63 970-978
• 48 Carr B R, Breslau N A, Givens C. et al . Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for the treatment of hirsutism: a clinical research center study.  J Endocrinol Metab . 1995;  80 1169-1178
• 49 Yucelten D, Erenus M, Gurbuz O, Durmusoglu F. Recurrence rates of hirsutism after 3 different antiandrogen therapies.  J Am Acad Dermatol . 1999;  41 64-68
• 50 Rittmaster R S. Clinical review 73: medical treatment of androgen dependent hirsutism.  J Clin Endocrinol Metab . 1995;  80 2559-2563
• 51 Carmina E, Lobo R A. Peripheral androgen blockade versus glandular suppression in the treatment of hirsutism.  Obstet Gynecol . 1991;  78 845-849
• 52 Mowszowicz I, Wright F, Vincens M. et al . Androgen metabolism in hirsute patients treated with cyproterone acetate.  J Steroid Biochem . 1984;  20 757-761
• 53 Hammerstein J, Meckies J, Leo-Rossberg I. et al . Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism.  J Steroid Biochem . 1975;  6 827-836
• 54 Young R L, Goldzieher J W, Elkind-Hirsch K. The endocrine effects of spironolactone used as an antiandrogen.  Fertil Steril . 1987;  48 223-228
• 55 Lobo R A, Shoupe D, Serafini P, Brinton D, Horton R. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women.  Fertil Steril . 1985;  43 200-205
• 56 Evans D J, Burke C W. Spironolactone in the treatment of idiopathic hirsutism and the polycystic ovarian syndrome.  J R Soc Med . 1986;  79 451-453
• 57 Barth J H, Cherry C A, Wojnarowaka F, Dawber R P. Spironolactone is an effective and well tolerated systemic anti-androgen therapy for hirsute women.  J Clin Endocrinol Metab . 1989;  68 966-970
• 58 McMullen G R, Van Herle J A. Hirsutism and the effectiveness of spironolactone in its management.  J Endocrinol Invest . 1993;  16 925-932
• 59 Cumming D C, Yang J C, Rebar R W, Yen S SC. Treatment of hirsutism with spironolactone.  JAMA . 1982;  247 1295-1298
• 60 Chapman M G, Dowsett M, Dewhurst C J, Jeffcoate S L. Spironolactone in combination with an oral contraceptive: an alternative treatment of hirsutism.  Br J Obstet Gynaecol . 1985;  92 983-985
• 61 Simard J, Luthy I, Guay J, Belanger A, Labrie F. Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues.  Mol Cell Endocrinol . 1986;  44 261-270
• 62 Muderris I I, Bayram F, Sahin Y, Kelestimur F. A comparison of two doses of flutamide (250 mg/d and 500 mg/d) in the treatment of hirsutism.  Fertil Steril . 1997;  68 644-647
• 63 Erenus M, Gurbuz O, Durmusoglu F. et al . Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism.  Fertil Steril . 1994;  61 613-616
• 64 Moghetti P, Tosi F, Tosi A. et al . Comparison of spironolactone, flutamide and finasteride in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial.  J Clin Endocrinol Metab . 2000;  85 90-94
• 65 Cusan L, Dupont A, Gomez J L, Tremblay R R, Labrie F. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial.  Fertil Steril . 1994;  61 281-287
• 66 Lapointe J, Fournier A, Richard V, Labrie C. Androgens down-regulate bcl-2 protooncogenes expression in ZR-75-1 human breast cancer cells.  Endocrinology . 1999;  140 416-421
• 67 Tolino A, Petrone A, Sarnacchiaro F. et al . Finasteride in the treatment of hirsutism: new therapeutic perspectives.  Fertil Steril . 1996;  66 61-65
• 68 Fruzzetti F, Delorenzo D, Parini D, Ricci C. Effects of finasteride, a 5α-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women.  J Clin Endocrinol Metab . 1994;  79 831-835
• 69 Moghetti P, Castello R, Magnani C M. et al . Clinical and hormonal effects of the 5α-reductase inhibitor finasteride in idiopathic hirsutism.  J Clin Endocrinol Metab . 1994;  79 1115-1121
• 70 Ciotta L, Cianci A, Calogero A E. et al . Clinical and endocrine effects of finasteride, a 5α-reductase inhibitor, in women with idiopathic hirsutism.  Fertil Steril . 1995;  64 299-306
• 71 Ogawa H, Hattori M. Regulation mechanisms of hair growth.  Curr Probl Dermatol . 1983;  11 159-170
• 72 Hynd P L, Nancarrow M J. Inhibition of polyamine synthesis alters hair follicle function and fiber composition.  J Invest Dermatol . 1996;  106 249-253
• 73 Schrode K, Huber F, Staszak J. et al .Randomized, double-blind, vehicle-controlled safety and efficacy evaluation of eflornithine 15% cream in the treatment of women with excessive facial hair. Poster presented at American Academy of Dermatology Annual Meeting; March 11-14, 2000; San Francisco
• 74 Patient information leaflet and prescribing information for Vaniqa (Bristol-Myers Squibb) Available at: http//www.vaniqa.com/pdf/pi.pdf . 
• 75 Oh H-S, Smart R C. An estrogen receptor pathway regulated the telogen-anagen hair follicle transition and influences epidermal cell proliferation.  Proc Natl Acad Sci U S A . 1996;  93 12525-12530
• 76 Olsen E. Methods of hair removal.  J Am Acad Dermatol . 1999;  40 143-155
• 77 Schoen L A, Lazar P. The Look You Like.  New York: Marcel Dekker 1990: 133-144
• 78 Ramos-E-Silva M, De Castro C M, Carneiro L V. Hair removal.  Clin Dermatol . 2001;  19 437-444
• 79 Dierickx C. Hair removal by lasers and intense pulsed light sources.  Semin Cutan Med Surg . 2000;  19 267-275
• 80 Dierickx C, Alora M B, Dover J S. Laser hair removal.  Dermatol Clin . 1999;  17 357-366
• 81 Draelos Z. Cosmetics: an overview.  Curr Probl Dermatol . 1995;  7 43-64
• 82 Anderson R R, Parrish J A. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation.  Science . 1983;  220 24-27
• 83 Grossman M C, Dwyer P, Wiberley J. et al . PDT for hirsutism.  Lasers Surg Med . 1995;  7(suppl) 44-47
• 84 Wheeland R G. Laser-assisted hair removal.  Dermatol Clin . 1997;  15 469-477